Exelixis: What’s Ahead For 2020
Today, we revisit mid-cap oncology name Exelixis. There has been quite a bit of news on this concern over the past five weeks, including a tie-up with giant drug maker Roche. We review these events and update the investment case on Exelixis in 2020 in the paragraphs below. “Some of the biggest cases of mistaken identity are among intellectuals …
News story posted on 2020-01-19T09:32:00.0000000Z
